Icelandic biosimilars company and Humira (adalimumab) challenger Alvotech has scored a major win in a lawsuit brought by AbbVie (NYSE: ABBV), alleging theft of trade secrets.
The Chicagoan company accused Alvotech exec Rongzan Ho, a former employee, of taking “confidential and proprietary” data on the manufacturing of Humira with him when he left the firm.
As the world’s best-selling medicine reaches the end of its exclusivity period in the USA, multiple drug developers are gearing up to launch copycat versions in the coming period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze